UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 02/2011, Volume 364, Issue 8, pp. 772 - 774
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Gene Expression Regulation, Neoplastic | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - enzymology | Drug Resistance, Neoplasm | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | MAP Kinase Signaling System - drug effects | Sulfonamides - therapeutic use | Melanoma - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Indoles - pharmacology | Indoles - therapeutic use | Mutation | Care and treatment | Gene mutations | Melanoma | Therapeutics | Physiological aspects | Diagnosis | Research | Homeopathy | Materia medica and therapeutics | Proteins | Kinases | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Nature medicine, ISSN 1078-8956, 11/2013, Volume 19, Issue 11, pp. 1401 - 1409
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Adaptation, Physiological | Melanoma - metabolism | Neoplasms - metabolism | raf Kinases - antagonists & inhibitors | Humans | Drug Resistance, Neoplasm | MAP Kinase Signaling System | Neoplasms - drug therapy | Neoplasms - genetics | Melanoma - genetics | Models, Biological | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Mutation | Enzyme inhibitors | Oncology, Experimental | Development and progression | Research | Properties | Drug therapy | Drug resistance | Phosphotransferases | Cancer | Tumors | Inhibitor drugs | Kinases | Cancer therapies | Melanoma | Index Medicus
Journal Article
The Journal of pathology, ISSN 0022-3417, 01/2011, Volume 223, Issue 2, pp. 220 - 230
mutations | BRAF inhibitors | MEK inhibitors | KRAS | BRAF | cancer | EGFR inhibitors | Pathology | Oncology | Life Sciences & Biomedicine | Science & Technology | Neoplasms - metabolism | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | ras Proteins - antagonists & inhibitors | ras Proteins - metabolism | Proto-Oncogene Proteins - genetics | Signal Transduction - genetics | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | Neoplasms - genetics | Signal Transduction - drug effects | Proto-Oncogene Proteins B-raf - genetics | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Mice | Mutation | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Index Medicus
Journal Article
Cancer cell, ISSN 1535-6108, 09/2015, Volume 28, Issue 3, pp. 370 - 383
Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | ras Proteins - genetics | Drug Resistance, Neoplasm - genetics | MAP Kinase Signaling System - drug effects | MAP Kinase Signaling System - genetics | Proto-Oncogene Proteins B-raf - genetics | Humans | Cell Line, Tumor | Protein Kinase Inhibitors - pharmacology | Mutation - genetics | Dimerization | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Nature (London), ISSN 0028-0836, 12/2011, Volume 480, Issue 7377, pp. 387 - 390
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | General aspects | Dermatology | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Humans | Melanoma - enzymology | Extracellular Signal-Regulated MAP Kinases - metabolism | Protein Isoforms - metabolism | Protein Isoforms - chemistry | Protein Multimerization - genetics | Indoles - pharmacology | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins B-raf - chemistry | Melanoma - metabolism | Alternative Splicing - genetics | Mutant Proteins - genetics | Exons - genetics | Mutant Proteins - metabolism | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Drug Resistance, Neoplasm - genetics | Animals | MAP Kinase Signaling System - drug effects | Proto-Oncogene Proteins B-raf - genetics | Mutant Proteins - chemistry | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Protein Multimerization - drug effects | Drug Resistance, Neoplasm - drug effects | Protein Isoforms - genetics | Cellular proteins | Melanoma | Physiological aspects | Genetic aspects | Research | Drug therapy | Health aspects | Index Medicus
Journal Article
6.
Full Text
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Nature (London), ISSN 0028-0836, 07/2012, Volume 487, Issue 7408, pp. 500 - 504
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Proto-Oncogene Proteins c-met - metabolism | Prognosis | Coculture Techniques | Humans | Antineoplastic Agents - therapeutic use | Phosphatidylinositol 3-Kinases - metabolism | Tumor Microenvironment - physiology | Molecular Targeted Therapy | Melanoma - genetics | Stromal Cells - drug effects | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Melanoma - metabolism | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Stromal Cells - metabolism | Antineoplastic Combined Chemotherapy Protocols | Melanoma - pathology | Sulfonamides - pharmacology | Hepatocyte Growth Factor - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Signal Transduction - drug effects | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Proteomics | Cell Line, Tumor | Indoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Mutation | Stromal Cells - cytology | Drug Resistance, Neoplasm - drug effects | Care and treatment | Physiological aspects | Genetic aspects | Research | Gene expression | Drug resistance | Growth factors | Health aspects | Liver cells | Cancer | Cytotoxicity | Epidermal growth factor | FDA approval | Cancer therapies | Tumors | Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 03/2020, Volume 26, Issue 5, pp. 1077 - 1085
Journal Article
Cancer, ISSN 0008-543X, 02/2013, Volume 119, Issue 3, pp. 548 - 554
BRAF | ovarian cancer | outcomes | early stage disease | low‐grade serous ovarian cancer | low-grade serous ovarian cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Biological and medical sciences | Medical sciences | Tumors | Female genital diseases | Prognosis | Early Detection of Cancer - methods | Proto-Oncogene Proteins B-raf - physiology | Glutamic Acid - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Ovarian Neoplasms - mortality | Ovarian Neoplasms - genetics | Neoplasm Grading | Female | Ovarian Neoplasms - diagnosis | Biomarkers, Tumor - physiology | Cystadenoma, Serous - diagnosis | Mutation, Missense - physiology | Cystadenoma, Serous - mortality | Amino Acid Substitution - physiology | Proto-Oncogene Proteins B-raf - genetics | Survival Analysis | Amino Acid Substitution - genetics | Valine - genetics | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging | Cystadenoma, Serous - genetics | Cystadenoma, Serous - pathology | Care and treatment | Research | Diagnosis | Gene mutations | Oncogenes | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Cancer research (Chicago, Ill.), ISSN 0008-5472, 12/2017, Volume 77, Issue 23, pp. 6513 - 6523
Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Colonic Neoplasms - genetics | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | raf Kinases - antagonists & inhibitors | Humans | Melanoma - pathology | Mice, SCID | raf Kinases - metabolism | HT29 Cells | Monomeric GTP-Binding Proteins - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Animals | Monomeric GTP-Binding Proteins - metabolism | Melanoma - genetics | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Dimerization | Tyrosine | Epidermal growth factor receptors | Colorectal carcinoma | Colorectal